Achieve Life Sciences, Inc. (ACHV)
$
5.24
+0.29 (5.53%)
Key metrics
Financial statements
Free cash flow per share
-1.1451
Market cap
267.8 Million
Price to sales ratio
1.2 Thousand
Debt to equity
0.2390
Current ratio
6.6375
Income quality
0.7878
Average inventory
0
ROE
-1.9349
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Achieve Life Sciences, Inc. is a clinical-stage pharmaceutical company that focuses on the development and commercialization of cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The operating income ratio is 0.00 indicating the company's operational profitability margin. The gross profit ratio is 0.00 reflecting the efficiency of the company's production and sales operations. However, the company reported a net loss of -$39,827,000.00 indicating challenges in its operations. The operating expenses amount to $38,840,000.00 encompassing various operational costs incurred. On a positive note, the gross profit stands at -$229,000.00 highlighting the company's profitability from core operations. This demonstrates the potential of cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain to reduce the severity of nicotine withdrawal symptoms, further solidifying the company's position within the pharmaceutical field. Based in Vancouver, Canada, Achieve Life Sciences has also secured license agreements with Sopharma AD and the University of Bristol, enhancing its collaborative efforts in advancing treatment options. In terms of investment potential, the stock is affordable at $2.82 making it suitable for budget-conscious investors. Notably, the stock has a low average trading volume of 1,507,056.00 indicating lower market activity, which may appeal to certain investment strategies. With a market capitalization of $267,790,032.00 the company is classified as a small-cap player, which often offers growth opportunities in the early stages of development. It is a key player in the Biotechnology industry, contributing significantly to the overall market landscape. Additionally, it belongs to the Healthcare sector, driving innovation and growth. This strategic positioning presents a unique opportunity for investors who are looking to support groundbreaking advancements in smoking cessation and nicotine addiction solutions.
Is Achieve Life Sciences, Inc. (ACHV) a good investment?
Investing in Achieve Life Sciences, Inc. (ACHV) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C, with a Bullish outlook. Always conduct your own research before investing.
What is Achieve Life Sciences, Inc. (ACHV)'s stock forecast?
Analysts predict Achieve Life Sciences, Inc. stock to fluctuate between $1.84 (low) and $5.78 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Achieve Life Sciences, Inc.'s market capitalization?
As of 2025-10-30, Achieve Life Sciences, Inc.'s market cap is $267,790,032, based on 51,104,968 outstanding shares.
How does Achieve Life Sciences, Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Achieve Life Sciences, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Achieve Life Sciences, Inc. (ACHV) stock?
To buy Achieve Life Sciences, Inc. (ACHV) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for ACHV. Place an order (Market, Limit, etc.).
What is the best time to invest in Achieve Life Sciences, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
Has Achieve Life Sciences, Inc. stock ever split?
Achieve Life Sciences, Inc.'s last stock split was 1:20 on 2020-07-31.
How did Achieve Life Sciences, Inc. perform in the last earnings report?
Revenue: $0 | EPS: -$1.24 | Growth: -17.33%.
Where can I find Achieve Life Sciences, Inc.'s investor relations reports?
Visit https://www.achievelifesciences.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Achieve Life Sciences, Inc.?
You can explore historical data from here
What is the all-time high and low for Achieve Life Sciences, Inc. stock?
All-time high: $10.30 (2023-05-11) | All-time low: $1.84 (2025-04-09).
What are the key trends affecting Achieve Life Sciences, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
globenewswire.com
SEATTLE and VANCOUVER, British Columbia, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence for smoking cessation, today announced it will report its third quarter 2025 financial results and provide a corporate update on the cytisinicline development program on Thursday, November 6, 2025, at 8:30 AM EST.
globenewswire.com
New life sciences executive brings more than 25 years of legal expertise spanning clinical and commercial stage biopharmaceutical companies New life sciences executive brings more than 25 years of legal expertise spanning clinical and commercial stage biopharmaceutical companies
seekingalpha.com
Achieve Life Sciences maintains its 'Buy' rating as the FDA accepts the NDA for cytisinicline for smoking cessation, with a PDUFA date set for June 20, 2026. ACHV's expansion into e-cigarette and vaping cessation is promising, supported by positive Phase 2 ORCA-V1 results and a Commissioner's National Priority Voucher from the FDA. Cytisinicline demonstrated a 2.6x higher quit rate vs. placebo in vaping cessation, and the FDA confirmed that a Phase 3 trial, plus ORCA-V1, could support an sNDA.
globenewswire.com
Potential First-in-Class Treatment for Nicotine E-cigarette or Vaping Cessation Receives Unprecedented Expedited Review Pathway
globenewswire.com
New data address critical treatment gap for millions of Americans with COPD who face unique smoking cessation challenges New data address critical treatment gap for millions of Americans with COPD who face unique smoking cessation challenges
globenewswire.com
SEATTLE and VANCOUVER, British Columbia, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline for treatment of nicotine dependence for smoking cessation, today announced Mark Rubinstein, M.D., will assume the role of Interim Chief Medical Officer (CMO). Dr. Rubinstein will succeed Cindy Jacobs, Ph.D., M.D., who we anticipate will provide advisory services to support the company's ongoing efforts to advance cytisinicline as a potential treatment option for nicotine dependence.
globenewswire.com
Filing based on pivotal Phase 3 ORCA-2 and ORCA-3 clinical trials demonstrating statistically significant and clinically meaningful smoking cessation FDA acceptance starts the review process and sets timing for potentially the first new FDA-approved pharmacotherapy in two decades PDUFA targeted date set for June 20, 2026 SEATTLE and VANCOUVER, British Columbia, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline for treatment of nicotine dependence, today announced that the U.S. Food and Drug Administration (FDA) has accepted the cytisinicline New Drug Application (NDA) for a new treatment for smoking cessation in adults.
globenewswire.com
SEATTLE and VANCOUVER, British Columbia, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence for smoking cessation, today announced that Rick Stewart, CEO of Achieve Life Sciences, will be participating at two upcoming conferences. Details are as follows:
benzinga.com
Achieve Life Sciences Inc. ACHV is moving closer to a pivotal moment as it seeks FDA approval for cytisinicline, a potential first new smoking cessation therapy in nearly two decades, positioning the company for a high-stakes commercial launch in 2026.
See all news
